“…In the TCA cycle, the mutation of IDH1/2 can also cause inconsistent changes in some metabolic intermediates, such as 2-OG, citrate, cis-aconite, isocitrate, and fumarate [ 245 , 249 , 250 , 251 , 252 , 253 , 254 ]. However, compared with WT–IDH cells that are dominated by glycolysis [ 255 , 256 ], IDH mutant tumour cells have a stronger TCA cycle [ 256 , 257 , 258 ], more OXPHOS [ 259 ], and lower glycolysis levels [ 256 , 260 , 261 ]. This may be related to using different carbon sources after the IDH mutation.…”